A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Dr. JohnC.S.Breitner, M.D.,M.P.H.
Pfizer Professor and Chair
Geriatric Psychiatry, Preventive Medicine
Douglas Mental Health Research Institute
6875 LaSalle Blvd, Pavillon Perry (E-2211)
514-761-6131 ext. 3940
Dr. Breitner has devoted his career to the study of Alzheimer’s disease (AD), its risk factors, and their implications for its prevention. Although an expert clinician, he is better known as a researcher. His early work on familial aggregation in AD evolved to twin studies of heritability and environmental risk factors. He then founded the Cache County Study of Memory in Aging, a longitudinal investigation of genetic and environmental antecedents of AD, which has produced over 100 scientific papers. More recently he was Chair of the randomized placebo-controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) that evaluated two nonsteroidal anti-inflammatory drugs for primary prevention of AD in healthy elderly. As that trial winds down, he recently joined the McGill faculty to establish the new StoP-AD Centre at the Douglas. This Centre is devoted to identification and quantitation of AD markers in the pre-symptomatic stage of the disease, and to preliminary testing of experimental strategies for that may prevent progression of pre-symptomatic disease to dementia. Dr. Breitner is has mentored more than 15 individuals who have gone on to tenure-track academic positions, nine of these whom have independent NIH funding, 3 are now Chairs and one the Executive Editor of a leading Alzheimer’s disease journal.
Residency: Oregon Health Sciences University (Psychiatry and General Preventive Medicine)
Fellow, American Psychopathological Association
Fellow, American College of Neuropsychopharmacology
Lifetime member, Delta Omega Honorary Public Health Society
Breitner JC, Baker LD*, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN; ADAPT Research Group. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement 2011;7:402-11.
ADAPT Research Group, Martin BK, Szekely C*, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008;65:896-90
ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800-8. Epub 2008 May 12.
Khachaturian AS*, Zandi PP*, Lyketsos CG, Hayden KM*, Skoog I, Norton MC*, Tschanz JT*, Mayer LS, Welsh-Bohmer KA, Breitner JC. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63:686-692.
Khachaturian AS*, Corcoran C, Mayer LS, Zandi PP*, Breitner JC, Cache County Study Investigators. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 2004;61(5):518-524.
Zandi PP*, Anthony JC, Khachaturian AS*, Stone SV, Gustafson D, Tschanz JT*, Norton MC*, Welsh-Bohmer KA, Breitner JC. Reduced risk of alzheimer disease in users of antioxidant vitamin supplements: The cache county study. Arch Neurol 2004;61:82-88.
Zandi PP*, Carlson MC*, Plassman BL*, WelshBohmer KA, Mayer LS, Steffens DC*, Breitner JCS. Hormone replacement therapy and incidence of alzheimer disease in older women - the cache county study. JAMA Journal of the American Medical Association 2002;288:2123-2129.
Plassman BL*, Havlik RJ, Steffens DC*, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, Guralnik JM, Breitner JC. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology. 2000;55:1158-1166.
Breitner JCS, Gau BA, Welsh KA, Plassman BL*, McDonald WM*, Helms MJ, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-232.
Breitner JCS, Folstein MF. Familial Alzheimer dementia: a prevalent disorder with specific clinical features. Psychological Medicine 1984;14:63-80.